Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR AMPLIFICATION ( ENST00000275493.7 )
EGFR AMPLIFICATION ( ENST00000275493.7 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/948
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/190
Rating
4
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
20826716
Drugs
Drug NameSensitivitySupported
Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorSensitivitytrue